Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study-Reference-Cited by-同舟云学术

Patients' preferences for once‐daily oral versus once‐weekly injectable diabetes medications: The REVISE study

Published:2020-12-13 Issue:2 Volume:23 Page:508-519
ISSN:1462-8902
Container-title:Diabetes, Obesity and Metabolism
language:en
Short-container-title:Diabetes Obes Metab

Author:

Boye Kristina¹,Ross Melissa²^ORCID,Mody Reema³,Konig Manige⁴,Gelhorn Heather⁵^ORCID

Affiliation:

1. Eli Lilly and Company Indianapolis Indiana USA

2. Evidera Inc Bethesda Maryland USA

3. Eli Lilly and Company Indianapolis Indiana USA

4. Eli Lilly and Company Indianapolis Indiana USA

5. Evidera Inc Bethesda Maryland USA

Funder

Eli Lilly and Company

Publisher

Wiley

Subject

Endocrinology,Endocrinology, Diabetes and Metabolism,Internal Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/dom.14244

Reference19 articles.

1. Centers for Disease Control (CDC) Newsroom. New CDC Report: More than 100 million Americans have diabetes or prediabetes. [Press Release]. Juy 18 2017.https://www.cdc.gov/media/releases/2017/p0718-diabetes-report.html. Accessed May 18 2020.

2. Diabetes UK. Key statistics on diabetes. Diabetes in the UK 2018. 2020;https://www.diabetes.org.uk/professionals/position-statements-reports/statistics. Accessed May 18 2020.

3. 2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)

4. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Medical Care in Diabetes—2020

5. EliLilly: Instructions for use: TRULICITY (TRU‐li‐si‐tee) (dulaglutide) injection for subcutaneous use 0.75 mg/0.5 mL Single‐Dose Pen use 1 time each week (once weekly). 2020;https://uspl.lilly.com/trulicity/trulicity.html#ug. Accessed May 18 2020.

Cited by 44 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Medication adherence to sodium‐glucose cotransporter‐2 inhibitors versus glucagon‐like peptide‐1 receptor agonists: A meta‐analysis;Diabetes, Obesity and Metabolism;2024-07-23

2. Barriers and Strategies to Optimize the Use of Glucagon-Like Peptide 1 Receptor Agonists in People with Type 2 Diabetes and High Cardiovascular Risk or Established Cardiovascular Disease: A Delphi Consensus in Spain;Advances in Therapy;2024-07-22

3. First in class, best in class or a wild card: who will dominate the anti-obesity medication market?;Journal of Comparative Effectiveness Research;2024-07

4. Preference for a Novel Oral Alternative to Parenterally Administered Medications;Patient Preference and Adherence;2024-07

5. Pharmaceutical Digital Design: From Chemical Structure through Crystal Polymorph to Conceptual Crystallization Process;Crystal Growth & Design;2024-06-24